Use of a Unique Mobile Medical Asset in COVID Monoclonal Antibody Treatment

Use of a Unique Mobile Medical Asset in COVID Monoclonal Antibody Treatment

The COVID-19 pandemic and the subsequent surge of patients presented to emergency departments has forever changed the paradigm of delivering emergency care. The highly infectious nature of the 2019 Novel Coronavirus, or COVID-19, mandated strict environmental changes, novel patient care, and flexibl...

Full description

Bibliographic Details
Main Authors:	Herman Morchel, David Clark, Leighanne Buenvenida, Chinwe Ogedegbe
Format:	Article
Language:	English
Published:	MDPI AG 2021-08-01
Series:	Healthcare
Subjects:	COVID-19 Mobile Satellite Emergency Department COVID monoclonal antibody treatment Bamlanivimab COVID-19 patient isolation COVID-19 patient treatment area
Online Access:	https://www.mdpi.com/2227-9032/9/8/990

Similar Items

Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis
by: Yu-Lin Tai, et al.
Published: (2023-05-01)

Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial
by: Himanshu P. Upadhyaya, et al.
Published: (2023-06-01)

Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern
by: Fulvia Mazzaferri, et al.
Published: (2022-11-01)

The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms
by: Robert W. Cross, et al.
Published: (2023-11-01)

Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy
by: Daniele Focosi, et al.
Published: (2022-07-01)

Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19
by: Valentina Mazzotta, et al.
Published: (2022-04-01)

Single Center Experience Using Monoclonal COVID-19 Antibodies in the Management of Immunocompromised Patients with COVID-19
by: David Klank, et al.
Published: (2022-12-01)

Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital
by: Judith Pannier, et al.
Published: (2023-02-01)

Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy
by: Valentine Marie Ferré, et al.
Published: (2022-10-01)

Monoclonal Antibodies for COVID-19 Treatment: Is It an Option in Indonesia?
by: Alvina Widhani
Published: (2023-07-01)

Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature
by: Serena Vita, et al.
Published: (2022-08-01)

Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies
by: Juan C. Almagro, et al.
Published: (2022-08-01)

Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection
by: Lorenza Romani, et al.
Published: (2022-03-01)

Clinical Impact of Monoclonal Antibodies in the Treatment of High-Risk Patients with SARS-CoV-2 Breakthrough Infections: The ORCHESTRA Prospective Cohort Study
by: Alessia Savoldi, et al.
Published: (2022-08-01)

Are monoclonal antibodies effective in patients with severe obesity in SARS‐CoV‐2 infected?
by: Claudio Ucciferri, et al.
Published: (2023-02-01)

SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab
by: Martin Heller, et al.
Published: (2023-04-01)

Retrospective Analysis of Vaccinated and Unvaccinated COVID-19 Patients Treated with Monoclonal Antibodies (mAb) and Their Emergent Needs (RAVEN)
by: Gordana Simeunovic, et al.
Published: (2023-03-01)

COVID-19 monoclonal antibody treatment impact on symptoms and post-COVID conditions among high-risk patients at a Federally Qualified Health Center
by: Natalie L. Vawter, et al.
Published: (2023-02-01)

Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria Region
by: Antonio Vena, et al.
Published: (2021-10-01)

Lung Ultrasound Is Useful for Evaluating Lung Damage in COVID-19 Patients Treated with Bamlanivimab and Etesevimab: A Single-Center Pilot Study
by: Sebastiano Cicco, et al.
Published: (2023-01-01)

Safety of Tocilizumab in COVID-19 Patients and Benefit of Single-Dose: The Largest Retrospective Observational Study
by: Ayman M. Al-Qaaneh, et al.
Published: (2022-03-01)

Use of Monoclonal Antibodies in Pregnant Women Infected by COVID-19: A Case Series
by: Pietro Crispino, et al.
Published: (2023-07-01)

Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort
by: Jorge Calderón-Parra, et al.
Published: (2023-01-01)

Assessment of the efficiency of treatment of patients with COVID-19 (literature review)
by: V.D. Moskaliuk, et al.
Published: (2024-04-01)

Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations
by: Juthaporn Cowan, et al.
Published: (2023-09-01)

Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews
by: Thuan Tong Tan, et al.
Published: (2023-12-01)

The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India
by: Aneesh Puthiyedath Joy, et al.
Published: (2022-03-01)

Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases
by: Aishwarya Mary Johnson, et al.
Published: (2021-09-01)

Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection
by: Price JK, et al.
Published: (2023-04-01)

Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID
by: Maria Grazia Cusi, et al.
Published: (2023-02-01)

Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients
by: David J. Douin, et al.
Published: (2022-11-01)

A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19
by: Syed Mohammed Basheeruddin Asdaq, et al.
Published: (2021-11-01)

Pre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients
by: Jowita Frączkiewicz, et al.
Published: (2024-03-01)

Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data
by: Antonio Russo, et al.
Published: (2024-01-01)

Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study
by: Simona Biscarini, et al.
Published: (2022-08-01)

Monoclonal antibody infusion reaction with bamlanivimab and etesevimab in a 5-year-old male with coronavirus disease 2019: a case report
by: Rajapillai L. I. Pillai, et al.
Published: (2023-02-01)

Real-World Experience of the Comparative Effectiveness and Safety of Combination Therapy with Remdesivir and Monoclonal Antibodies versus Remdesivir Alone for Patients with Mild-to-Moderate COVID-19 and Immunosuppression: A Retrospective Single-Center Study in Aichi, Japan
by: Jun Hirai, et al.
Published: (2023-09-01)

Monoclonal antibody therapy for COVID-19 during pregnancy
by: Diana I. Abdulganieva, et al.
Published: (2023-09-01)

Long-term cellular immune response in immunocompromised unvaccinated COVID-19 patients undergoing monoclonal antibody treatment
by: Laura Thümmler, et al.
Published: (2022-10-01)

A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic
by: Alberto Zaniboni, et al.
Published: (2020-08-01)